Stem cell mobilization in heavily pretreated multiple myeloma patients with prior high dose melphalan and auto-SCT

摘要

Salvage second auto-SCT (ASCT) is a reasonable treatment option for patients with relapsed multiple myeloma (MM) when the duration of remission after initial ASCT is longer than 12-18 months. In addition, second salvage autologous transplant may be used in the context of progressive refractory myeloma for temporary disease control or for hematopoietic reconstitution after prior extensive therapy. Customarily, patients with MM who received prior alkylating agents or autologous transplantation with high-dose melphalan are not considered to be transplant candidates because of the deleterious effects of the drugs on stem cell collection.